Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary A Single Ascending-Dose Study of Muscle Regulator ACE-031 in Healthy Volunteers. Muscle & Nerve. November 21 2012. [ePub ahead of print]
A Single Ascending-Dose Study of Muscle Regulator ACE-031 in Healthy Volunteers. Muscle & Nerve. November 21 2012. [ePub ahead of print] Link to abstract
View HTML
Toggle Summary A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46(4):1082-8
A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46(4):1082-8 Link to abstract
View HTML
Toggle Summary A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. Endocrinology 2010; 151(9): 4289–4300
A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. Endocrinology 2010; 151(9): 4289–4300 A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health.
View HTML
Toggle Summary A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087 A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087
View HTML
Toggle Summary A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. PNAS 2012; 109(30):12207-12212
A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. PNAS 2012; 109(30):12207-12212 Link to abstract
View HTML
Toggle Summary Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene
View HTML
Toggle Summary Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting
Sotatercept produces dose dependent increases in hemoglobin with no dose dependent changes in blood pressure CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel
View HTML
Toggle Summary Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology
- Preliminary results show that treatment with investigational drug sotatercept can increase hemoglobin and achieve transfusion independence in patients with myelofibrosis - - Acceleron to host conference call and live webcast on Monday, December 5 th at 9:00 a.m. EST ( 6:00 a.m.
View HTML
Toggle Summary Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
- Longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden, and improved patient reported quality of life measures in patients with beta-thalassemia - - Acceleron to host conference call and live webcast today at 8:00 a.m.
View HTML
Toggle Summary Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
- Preliminary results show that treatment with investigational drug luspatercept results in clinically meaningful increases in hemoglobin and durable transfusion independence in patients with lower risk myelodysplastic syndromes - - Acceleron to host conference call and live webcast today at 8:00
View HTML